Dendreon Corporation to Host Conference Call Monday, January 12, 2004.Business Editors/Health/Medical Writers BIOWIRE2K SEATTLE--(BUSINESS WIRE)--Jan. 9, 2004 Company to Provide Clinical Update on Provenge(R) Survival Results from First Completed Phase 3 Trial (D9901) Dendreon Dendreon is a Seattle based biotechnology company. Its leading product candidate, Sipuleucel-T (known as Provenge during drug trials), is an immunotherapy for prostate cancer. Corporation (Nasdaq:DNDN) today announced that it will host a conference call Monday, January 12, 2004 at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time). Mitchell Mitchell, city (1990 pop. 13,798), seat of Davison co., SE S.Dak.; inc. 1881. Mitchell is a trade, distribution, and shipping center for a dairy and livestock area. H. Gold, M.D., president and chief executive officer of Dendreon, and other members of Dendreon management, along with John Corman, M.D., director of the Virginia Virginia, state, United States Virginia, state of the south-central United States. It is bordered by the Atlantic Ocean (E), North Carolina and Tennessee (S), Kentucky and West Virginia (W), and Maryland and the District of Columbia (N and NE). Mason Comprehensive Prostate Cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. Clinic and assistant clinical professor of urology urology Medical specialty dealing with the urinary system and male reproductive organs. It traces its origin to medieval lithologists, itinerant healers who specialized in surgical removal of bladder stones. at the University of Washington in Seattle, will provide a clinical update focused primarily on updated survival data from the Company's first completed Phase 3 trial (D9901) of Provenge(R), Dendreon's lead investigational product candidate for the treatment of prostate cancer. To access the call, please dial 888-323-9686 (domestic) or 210-234-0006 (international). The passcode for the call is "Dendreon." A replay of the call will be available by phone at 800-925-4850 (domestic) or 402-220-4323 (international). Except for historical information contained herein, this news release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. . Factors that may cause such a difference include risks related to the uncertainty of Dendreon's future access to capital, Dendreon's limited operating history, risks associated with completing Dendreon's clinical trials, the risk that the safety and/or efficacy results of a clinical trial will not support an application for a biologics license, the risk that the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. will not approve a product for which a biologics license has been applied, the failure by Dendreon to secure and maintain relationships with collaborators, dependence on the efforts of third parties, and dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations, are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion